|Articles|September 16, 2013
What is Misunderstood about RBM
A conversation with Marc Buyse, founder of CluePoints on risk based monitoring in clinical trials
Advertisement
A conversation with Marc Buyse, founder of CluePoints on risk based monitoring in clinical trials
This video is part of a series of conversations on
For more videos of Marc Buyse, see also:
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
2
Generative AI Transforms Clinical Study Report Development
3
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
4
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
